WO2007048022A3 - Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation - Google Patents

Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation Download PDF

Info

Publication number
WO2007048022A3
WO2007048022A3 PCT/US2006/041215 US2006041215W WO2007048022A3 WO 2007048022 A3 WO2007048022 A3 WO 2007048022A3 US 2006041215 W US2006041215 W US 2006041215W WO 2007048022 A3 WO2007048022 A3 WO 2007048022A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
methods
constant domain
producing
same
Prior art date
Application number
PCT/US2006/041215
Other languages
English (en)
Other versions
WO2007048022A2 (fr
Inventor
Anke Kretz-Rommel
Naveen Dakappagari
Martha Wild
Cecilia Orencia
Katherine S Bowdish
David R Gies
Jeremy P Springhorn
Original Assignee
Alexion Pharma Inc
Anke Kretz-Rommel
Naveen Dakappagari
Martha Wild
Cecilia Orencia
Katherine S Bowdish
David R Gies
Jeremy P Springhorn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Anke Kretz-Rommel, Naveen Dakappagari, Martha Wild, Cecilia Orencia, Katherine S Bowdish, David R Gies, Jeremy P Springhorn filed Critical Alexion Pharma Inc
Publication of WO2007048022A2 publication Critical patent/WO2007048022A2/fr
Publication of WO2007048022A3 publication Critical patent/WO2007048022A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des fusions d'anticorps dans lesquelles un peptide est incorporé dans le domaine constant d'un anticorps. Les peptides peuvent être incorporés au niveau de zones hydrophobes du domaine constant et/ou entre des sites de clivage protéasomique naturels ou introduits. L'invention concerne également des fusions d'anticorps dans lesquelles un peptide est rattaché à la terminaison C du domaine constant d'une chaîne lourde ou légère d'anticorps par l'intermédiaire d'un élément de liaison de clivage. L'invention concerne également des méthodes d'utilisation des fusions d'anticorps comprenant des applications thérapeutiques telles que la modulation immune et la suppression sélective des cellules, et des applications de recherche telles que des dosages de criblage pour identifier l'internalisation des anticorps ou des agents cytotoxiques.
PCT/US2006/041215 2005-10-21 2006-10-20 Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation WO2007048022A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72940405P 2005-10-21 2005-10-21
US60/729,404 2005-10-21

Publications (2)

Publication Number Publication Date
WO2007048022A2 WO2007048022A2 (fr) 2007-04-26
WO2007048022A3 true WO2007048022A3 (fr) 2007-09-13

Family

ID=37891461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041215 WO2007048022A2 (fr) 2005-10-21 2006-10-20 Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation

Country Status (1)

Country Link
WO (1) WO2007048022A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP7064670B2 (ja) 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． プロテアーゼで切断可能なリンカーを有するペプチド構築体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101538328B (zh) * 2007-06-15 2011-07-27 中国疾病预防控制中心病毒病预防控制所 一种人源中和性抗禽流感病毒h5n1基因工程抗体
CN101092456B (zh) * 2007-06-15 2010-11-10 中国疾病预防控制中心病毒病预防控制所 人源中和性抗禽流感病毒h5n1基因工程抗体
EP2168590A1 (fr) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Peptides antimicrobiens
SG173680A1 (en) * 2009-02-24 2011-09-29 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides
US11492383B2 (en) * 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2968546B1 (fr) * 2013-03-15 2023-09-20 Omeros Corporation Méthodes de génération d'anticorps porteurs de peptide bioactif et compositions les comprenant
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN105017428B (zh) * 2014-05-13 2018-09-11 中国人民解放军军事科学院军事医学研究院 双靶向融合蛋白及其编码基因与应用
WO2015188135A1 (fr) * 2014-06-06 2015-12-10 The California Institute For Biomedical Research Protéines de fusion à anticorps à région constante et compositions les contenant
EA035638B1 (ru) 2015-03-31 2020-07-20 ВиЭйчСКВЕАРД ЛИМИТЕД Полипептиды
UA123323C2 (uk) 2016-05-02 2021-03-17 Ф. Хоффманн-Ля Рош Аг Димерний злитий поліпептид
EP3519438A1 (fr) 2016-09-30 2019-08-07 VHsquared Limited Compositions
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CA3078974A1 (fr) 2017-10-12 2019-04-18 Immunowake Inc. Proteine de fusion a chaine legere d'anticorps vegfr
KR102559706B1 (ko) 2017-11-01 2023-07-25 에프. 호프만-라 로슈 아게 Trifab-콘톨스바디
WO2019086394A1 (fr) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag "compbody" - lieur cible multivalent
US20210070854A1 (en) * 2017-12-29 2021-03-11 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
JP2021528390A (ja) * 2018-06-13 2021-10-21 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
CN114514243A (zh) 2019-06-21 2022-05-17 索瑞索制药公司 多肽
CN114466864A (zh) 2019-06-21 2022-05-10 索瑞索制药公司 多肽
CN114478783B (zh) * 2022-01-07 2022-11-29 陕西脉元生物科技有限公司 一种eno2单克隆抗体及其制备方法和应用
WO2023240215A1 (fr) * 2022-06-09 2023-12-14 The Children's Medical Center Corporation Procédés et compositions pour une présentation d'antigène améliorée dans le micro-environnement tumoral

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031483A1 (fr) * 1994-05-13 1995-11-23 Eclagen Limited Administration amelioree de peptides
WO1996022377A1 (fr) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation de lymphocytes t par des immunoglobulines antigeniques modifiees
WO2002088317A2 (fr) * 2001-05-01 2002-11-07 The Regents Of The University Of California Molecules hybrides et methodes de traitement des maladies immunitaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031483A1 (fr) * 1994-05-13 1995-11-23 Eclagen Limited Administration amelioree de peptides
WO1996022377A1 (fr) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation de lymphocytes t par des immunoglobulines antigeniques modifiees
WO2002088317A2 (fr) * 2001-05-01 2002-11-07 The Regents Of The University Of California Molecules hybrides et methodes de traitement des maladies immunitaires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU C ET AL: "FcgammaRI-targeted fusion proteins result in efficient presentation by human monocytes and antagonist T cell epitopes", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 9, 1 November 1996 (1996-11-01), pages 2001 - 2007, XP002131533, ISSN: 0021-9738 *
LUNDE E ET AL: "Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antige npresentation by B cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 17, 1999, pages 670 - 675, XP002227236, ISSN: 1087-0156 *
LUNDE E ET AL: "Troybodies and pepbodies", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 30, no. PART 4, 2002, pages 500 - 506, XP002227237, ISSN: 0300-5127 *
TUNHEIM GRO ET AL: "Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 77, no. 3, March 2005 (2005-03-01), pages 303 - 310, XP002432577, ISSN: 0741-5400 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP7064670B2 (ja) 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． プロテアーゼで切断可能なリンカーを有するペプチド構築体

Also Published As

Publication number Publication date
WO2007048022A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007048022A3 (fr) Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation
WO2007048037A3 (fr) Procedes pour la generation d'igg monovalente
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
EP2535351A3 (fr) Fusions d'anticorps à double spécificité
MY148646A (en) Anti-psgl-1 antibodies
EP2301570B8 (fr) Immunothérapie s'appliquant aux tumeurs malignes des lymphocytes B et maladies auto-immunes utilisant des anticorps non conjugués et des anticorps conjugués, des combinaisons d'anticorps et des protéines de fusion
EP2345671B8 (fr) Variantes FC optimisées et leurs procédés de génération
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
NZ600022A (en) Anti CD37 antibodies
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
PT1883698E (pt) Anticorpos monoclonais e fragmentos de anticorpo de cadeia única contra antigénio de membrana específico da próstata de superfície celular
WO2007106744A3 (fr) Anticorps anti-5t4 et leurs utilisations
WO2006031653A3 (fr) Anticorps anti-5t4 humanises et conjugues anticorps anti-5t4/calicheamicine
WO2006002161A3 (fr) Modulateurs de recepteurs odorants
WO2004049794A3 (fr) Anticorps simple chaine
WO2004041865A3 (fr) Anticorps a domaine unique stabilises
WO2007044616A3 (fr) Anticorps anti-cd30 optimises
EP2363416A3 (fr) Anticorps monoclonal dirigé contre la glycoprotéine VI plaquettaire
EP3970746A3 (fr) Variants polypeptidiques et leurs utilisations
WO2002099119A3 (fr) Acides nucleiques et polypeptides associes a b7 utiles pour l'immunomodulation
WO2007115230A3 (fr) Stratégie pour l'homodimérisation et l'hétérodimérisation de diverses protéines dans des solutions et dans des cellules
CY1110157T1 (el) Χιμαιρικα ανασυνδυασμενα αντιγονα του toxoplasma gondii
WO2008035217A3 (fr) Protéines de fusion comprenant deux ou plusieurs domaines de liaison igg d'une protéine g streptococcique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06817264

Country of ref document: EP

Kind code of ref document: A2